However, experts observed an increased threat of thrombosis in the darbepoetin alfa group. Researchers note that further research is required to identify treatment options because of this patient population.. Aarbepoetin alfa does not improve anemic heart failing patients’ health Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Medical center have discovered that a commonly used drug to take care of anemia in heart failing patients -darbepoetin alfa – does not improve patients' health, nor does it decrease their threat of death from center failure. Results of the international study were offered at the American University of Cardiology's annual meeting in SAN FRANCISCO BAY AREA on March 10 and published simultaneously online by the New England Journal of Medication.The review also looks ahead to the arrival of newly designed molecules that mimic the actions of insulin while avoiding triggering an allergic response. Furthermore new modes of drug delivery, such as constant subcutaneous insulin infusion , can help, and early reports suggest that CSII can help those who have previously had an allergic attack to insulin. Related StoriesGenovate begins building of Insulin Ecological Industrial Park in Changzhou National Hi-tech DistrictInsulin sensitivity of primary glucose storage space sites in the body improve pursuing gastric bypass surgeryHigher insulin levels linked to even worse prognosis in advanced breast cancer In the 1950s and 1960s more than half of patients who used insulin experienced some type of allergic attack.